Study In Patients With Kidney Cancer Treated With Sutent

Pfizer

Status: Completed

Conditions: Advanced or Metastatic Renal Cell Carcinoma; Renal Cancer

Treatments: Drug: Sutent

Study type: Observational

Funder types: Industry

Identifiers

NCT00873210

A6181185

Details and patient eligibility

About

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Full description

Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Enrollment: 121 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Exclusion criteria

• Hypersensitivity to sunitinib malate or to any of the excipients
• Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

Trial design

121 participants in 1 patient group

Patients treated with Sutent

Description:

125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Treatment:

Drug: Sutent